Drugs / Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04977479 | Sep 2021 → Jun 2022 | hypersensitivity reaction disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pfizer-BioNTech COVID-19 Vaccine, Bivalent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04977479 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA vaccine booster bivalent (Original and Omicron BA.4/BA.5) for the prevention of COVID-19.” NCT04977479 ↗ |
| Route | Intramuscular | “Single dose (0.3mL) via IM.” NCT04977479 ↗ |